SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 230 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,703 | -0.4% | 1,730,269 | +8.6% | 0.08% | +6.5% |
| Q2 2023 | $47,895 | -15.3% | 1,593,305 | +2.1% | 0.08% | -21.4% |
| Q1 2023 | $56,521 | +1.6% | 1,560,062 | +0.0% | 0.10% | -11.7% |
| Q4 2022 | $55,628 | -99.9% | 1,559,535 | -2.6% | 0.11% | +0.9% |
| Q3 2022 | $54,204,000 | +16.3% | 1,601,303 | -0.6% | 0.11% | +27.9% |
| Q2 2022 | $46,589,000 | -11.5% | 1,610,962 | -1.1% | 0.09% | +22.9% |
| Q1 2022 | $52,670,000 | +8.1% | 1,629,660 | -2.5% | 0.07% | +18.6% |
| Q4 2021 | $48,733,000 | +10.7% | 1,671,214 | +1.3% | 0.06% | +9.3% |
| Q3 2021 | $44,021,000 | -11.7% | 1,650,567 | +1.9% | 0.05% | -10.0% |
| Q2 2021 | $49,851,000 | +340.5% | 1,619,065 | +274.5% | 0.06% | +300.0% |
| Q1 2021 | $11,318,000 | +28.5% | 432,323 | +23.5% | 0.02% | +25.0% |
| Q4 2020 | $8,809,000 | +16.8% | 350,128 | -3.3% | 0.01% | +9.1% |
| Q3 2020 | $7,544,000 | -12.6% | 362,002 | -0.4% | 0.01% | -21.4% |
| Q2 2020 | $8,633,000 | +27.7% | 363,502 | -3.3% | 0.01% | 0.0% |
| Q1 2020 | $6,760,000 | -55.1% | 375,771 | -40.8% | 0.01% | -46.2% |
| Q4 2019 | $15,046,000 | -51.0% | 634,301 | -43.2% | 0.03% | -55.9% |
| Q3 2019 | $30,683,000 | -7.6% | 1,116,567 | +11.3% | 0.06% | -4.8% |
| Q2 2019 | $33,203,000 | +122.9% | 1,003,429 | +136.0% | 0.06% | +113.8% |
| Q1 2019 | $14,896,000 | +1.0% | 425,128 | -4.2% | 0.03% | -17.1% |
| Q4 2018 | $14,749,000 | -48.9% | 443,984 | -22.5% | 0.04% | -38.6% |
| Q3 2018 | $28,861,000 | -16.8% | 573,212 | -1.1% | 0.06% | -18.6% |
| Q2 2018 | $34,693,000 | +32.0% | 579,672 | +1.0% | 0.07% | +25.0% |
| Q1 2018 | $26,292,000 | +11.0% | 574,053 | -3.4% | 0.06% | +14.3% |
| Q4 2017 | $23,687,000 | -8.7% | 594,394 | -8.3% | 0.05% | -14.0% |
| Q3 2017 | $25,936,000 | -9.9% | 648,406 | -2.9% | 0.06% | -16.2% |
| Q2 2017 | $28,790,000 | +33.2% | 667,989 | -3.3% | 0.07% | +25.9% |
| Q1 2017 | $21,617,000 | +21.2% | 690,624 | -2.2% | 0.05% | +22.7% |
| Q4 2016 | $17,831,000 | -2.9% | 706,161 | -4.9% | 0.04% | -6.4% |
| Q3 2016 | $18,367,000 | +18.2% | 742,704 | -2.7% | 0.05% | +11.9% |
| Q2 2016 | $15,545,000 | +129441.7% | 763,128 | +96990.1% | 0.04% | – |
| Q1 2016 | $12,000 | +300.0% | 786 | +222.1% | 0.00% | – |
| Q4 2015 | $3,000 | – | 244 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |